Patient characteristics stratified on fludarabine exposure
| . | Fludarabine <4mg*h/L, n (%) . | Fludarabine ≥14 mg*h/L, n (%) . | P value . |
|---|---|---|---|
| AUC mg*h/L, median (range) | 11.9 (8.7-13.7) | 16.8 (14.0-21.8) | |
| Patients, n | 11 | 15 | |
| Age at infusion, years (range) | 11.6 (4.0-23.3) | 16.8 (5.1-24.5) | .8 |
| Male | 7 (64) | 8 (53) | .7 |
| Follow up, d (range) | 205 (107-695) | 408 (53-800) | .26 |
| MRD-negative CR on d 28 | 6 (55) | 14 (93) | .05 |
| Indication for CAR T therapy | 1 | ||
| Primary refractory | 2 (18) | 2 (13) | |
| Relapse | 9 (82) | 13 (87) | |
| Disease status at start of lymphodepletion | .68 | ||
| M1 marrow | 8 (73) | 9 (60) | |
| ≥M2 marrow | 3 (27) | 6 (40) | |
| Prior therapies, n | 1 | ||
| 1-2 | 9 (82) | 12 (80) | |
| 3-5 | 2 (18) | 3 (20) | |
| Prior blinatumomab | .66 | ||
| Yes | 2 (18) | 5 (33) | |
| No | 9 (82) | 10 (67) | |
| Prior allo-HCT | .7 | ||
| Yes | 4 (36) | 7 (47) | |
| No | 7 (64) | 8 (53) | |
| TP53 mutation | 1 | ||
| Yes | 1 (9) | 1 (7) | |
| No | 10 (91) | 14 (93) |
| . | Fludarabine <4mg*h/L, n (%) . | Fludarabine ≥14 mg*h/L, n (%) . | P value . |
|---|---|---|---|
| AUC mg*h/L, median (range) | 11.9 (8.7-13.7) | 16.8 (14.0-21.8) | |
| Patients, n | 11 | 15 | |
| Age at infusion, years (range) | 11.6 (4.0-23.3) | 16.8 (5.1-24.5) | .8 |
| Male | 7 (64) | 8 (53) | .7 |
| Follow up, d (range) | 205 (107-695) | 408 (53-800) | .26 |
| MRD-negative CR on d 28 | 6 (55) | 14 (93) | .05 |
| Indication for CAR T therapy | 1 | ||
| Primary refractory | 2 (18) | 2 (13) | |
| Relapse | 9 (82) | 13 (87) | |
| Disease status at start of lymphodepletion | .68 | ||
| M1 marrow | 8 (73) | 9 (60) | |
| ≥M2 marrow | 3 (27) | 6 (40) | |
| Prior therapies, n | 1 | ||
| 1-2 | 9 (82) | 12 (80) | |
| 3-5 | 2 (18) | 3 (20) | |
| Prior blinatumomab | .66 | ||
| Yes | 2 (18) | 5 (33) | |
| No | 9 (82) | 10 (67) | |
| Prior allo-HCT | .7 | ||
| Yes | 4 (36) | 7 (47) | |
| No | 7 (64) | 8 (53) | |
| TP53 mutation | 1 | ||
| Yes | 1 (9) | 1 (7) | |
| No | 10 (91) | 14 (93) |